# BrightSpring Health Services, Inc. (BTSG)

> Source: Nexqual · https://nexqual.com/BTSG · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, BrightSpring Health Services, Inc. (BTSG), nexqual.com/BTSG" · informational, not investment advice.

**Price:** USD 60.86 (-2.41% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 62.36 · day 59.79–62.04 · 52w 30.64–73.75 · market cap $12.0B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $14.4B, net income $366M (2.5% margin), free cash flow $402M (SEC filings).
- Valuation: P/E 32.9x (avg 43.2x at the last 1 fiscal year-ends), EV/EBITDA 22.5x, net debt $1.64B.
- 1 of 80 tracked superinvestors hold BTSG (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.83 on a 1–5 scale) (18 analysts), mean target USD 78.94 (range 70–90).
- Total return with dividends: 1Y +81.7% vs S&P 500 +14.9%; 5Y +453.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-30, EPS estimate USD 0.47, revenue estimate $3.87B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $7.72B | $7.69B | $10.1B | $12.9B | $14.4B |
| Gross profit | $1.35B | $1.14B | $1.27B | $1.52B | — |
| Operating income | $188M | $58.1M | $108M | $295M | $448M |
| Net income | -$53.9M | -$155M | -$18.1M | $191M | $366M |
| EPS (diluted) | -$0.46 | -$1.31 | -$0.09 | $0.87 | — |
| Free cash flow | -$74.8M | $137M | -$57.1M | $395M | $402M |
| Gross margin | 17.5% | 14.8% | 12.6% | 11.8% | — |
| Operating margin | 2.4% | 0.8% | 1.1% | 2.3% | 3.1% |
| Net margin | -0.7% | -2.0% | -0.2% | 1.5% | 2.5% |
| Revenue growth | — | -0.4% | +31.0% | +28.2% | — |
| Cash + short-term investments | — | $13.1M | $61.0M | $88.4M | — |
| Total debt | — | $3.36B | $2.61B | $2.51B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 32.9x · P/S 0.8x · EV/EBITDA 22.5x · EV/Sales 0.9x · P/FCF 29.9x · P/B 5.9x · FCF yield 3.34% · Earnings yield 3.04% · Net debt $1.64B · EV $13.7B
P/E at fiscal year-ends: Dec 2025 43.2x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold BTSG. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.32% | $113M | New position |

## Analysts
Consensus Buy (mean 1.83 on a 1–5 scale), 18 analysts; mean target USD 78.94 (low 70, high 90).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | BTIG | Reiterated | Buy | $90 |
| 2026-08-03 | BTIG | Reiterated | Buy | $90 |
| 2026-07-14 | Morgan Stanley | Target raised | Overweight | $71 → $80 |
| 2026-07-14 | Keybanc | Target raised | Overweight | $60 → $80 |
| 2026-07-13 | Wells Fargo | Target raised | Overweight | $61 → $78 |
| 2026-07-13 | Guggenheim | Initiated | Buy | $81 |
| 2026-07-10 | Raymond James | Initiated | Outperform | $80 |
| 2026-07-08 | UBS | Target raised | Buy | $63 → $85 |
| 2026-07-02 | B of A Securities | Target raised | Buy | $66 → $77 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2024-01-22) |
|---|---|---|
| Total return | +81.7% | +453.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +82.0% | +86.3% |
| Volatility (annualized) | 44.2% | 43.1% |
| Max drawdown | -23.6% (Jul 2026→Sep 2026) | -29.7% (Jan 2025→Apr 2025) |

## Peers (Health Information Services)
TEM (Tempus AI, Inc.) USD 63.81 -5.83% · HNGE (Hinge Health, Inc.) USD 109.93 -1.85% · HQY (HealthEquity, Inc.) USD 100.97 +3.16% · DOCS (Doximity, Inc.) USD 33.68 +0.30% · WAY (Waystar Holding Corp.) USD 28.98 +0.49% · HTFL (Heartflow, Inc.) USD 55.43 -0.70%

## More
Full page: https://nexqual.com/BTSG · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.47 | $0.44 | +7.8% | $3.87B | 16 |
| Next quarter (ends 2026-12-31) | $0.51 | $0.47 | +8.7% | $4.01B | 16 |
| Current fiscal year (ends 2026-12-31) | $1.82 | $1.69 | +7.7% | $15.37B | 17 |
| Next fiscal year (ends 2027-12-31) | $2.28 | $2.12 | +7.2% | $17.43B | 17 |